REFERENCES 1. American Diabetes Association. Introductions and methodology: standards of care in diabetes, 2023.Diabetes Care. 2023;46(suppl 1):s1-s291. doi:10.2337/dc23-Sint 2. Yu M, Mody R, Land√≥ LF, et al. Characteristics associated with the choice of first injectable therapy among us patients with type 2 diabetes. Clin Ther. 2017;39(12):2399-2408. doi:10.1016/j. clinthera.2017.11.001 3. Castellana M, Cignarelli A, Brescia F, Laviola L, Giorgino F. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: a systematic review and meta-analysis.Diabetes Metab Res Rev. 2019;35(1): e3082. doi:10.1002/dmrr.3082 